Green Lane Coordinating Centre Limited prides itself on providing quality clinical trial management solutions to the pharmaceutical, biotechnology and device industry.
It is our team of highly trained, experienced and motivated personnel who ensure that GLCC delivers a quality clinical trial solution to our clients every time. At GLCC we strongly believe people are our biggest asset.
Our dedicated team consists of project managers, clinical research associates, regulatory affairs specialists, and administrators who work with our management team in a supportive and collaborative environment. Together with support from national and international academia, research registrars and fellows, we are dedicated to achieving the highest possible standard in clinical research.
Our team constantly seeks to develop and utilise new tools and technologies in order to deliver the most efficient and cost-effective services to our clients.
Caroline Alsweiler – Managing Director, Clinical Trials Manager
BSc, PGDipHSc, MHSc, CCRA
Caroline Alsweiler started her career in clinical research at Guy’s Hospital, London. After a number of years she returned to New Zealand where she joined GLCC in early 2004.
During her involvement in the clinical research industry she has gained experience as a Senior Clinical Research Associate, Project Manager and Data Manager. She is highly skilled in all areas of clinical research with a depth of knowledge which covers many aspects of the industry. Caroline writes and conducts all of the industry training courses as part of her role at GLCC and is often invited to speak at industry events.
Caroline currently sits as a Steering Committee Member for ANZACT, the Australian and New Zealand Alliance for Cardiovascular Trials network. This network has been established to provide a framework to support the development and conduct of investigator-initiated high quality, multi-centre clinical trials and associated research activities.
Caroline is a Certified Clinical Research Associate with the Association of Clinical Research Professionals (US) and is a past member of the New Zealand Association of Clinical Research (NZACRes) Executive Committee.
Caroline currently sits on The University of Auckland Human Participants Ethics Committee.
Professor Harvey White -Clinical Director
MB ChB DSc FRACP FACC FESC FAHA FHKCC (Hon) FCSANZ FRSNZ
Honorary La’auli (Matai), Lalomalava, Samoa; Prince Mahidol Laureate, Honorary Clinical Professor of Medicine, University of Auckland, John Neutze Scholar
Director of Coronary Care & Green Lane Cardiovascular Research Unit, Green Lane Cardiovascular Service, Auckland City Hospital
Harvey White is the Director of the Acute Cardiac Care Unit and Cardiovascular Research Unit at the Green Lane Cardiovascular Service, Auckland City Hospital, New Zealand. He is an Honorary Professor of Medicine at the University of Auckland and Fellow of the Royal Society of New Zealand. He is co-director of the GLCC.
Harvey trained at Green Lane Hospital, Auckland and at Harvard and Brigham and Women’s Hospital, Boston, USA. In 2008, he attended a World Medical Association INSEAD Leadership Course, Fontainebleau, Paris, France
In recognition of his work on fibrinolysis and end-systolic volumes as prognostic factors, he was awarded a DSc by Otago University, Dunedin, New Zealand. He was awarded the 1998 Prince Mahidol Award for Medicine by the King of Thailand for introducing fibrinolytic therapy in many developing countries, including China. He is a Matai (Chief) in Samoa and has a “pou” in the Te Awamutu Walk of Fame. He has been the NZ Chairman and the President of the combined Australian and NZ Cardiac Society.
His citation for the NZ Royal Society states ‘for advocacy on behalf of patients’. He has advocated retaining the name ‘Patient’. He is an Advocate for more Automated External defibrillators (AEDs) and has a trust “Start a heart” for promoting greater number of AEDs.
He has been Chairman of the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM), Hirulog Early Reperfusion Occulsion (HERO) and STabilisation of Atherosclerotic plaque By Initiation of darapLadib TherapY (STABILITY) Trials. He is currently Co-chairman of the Redefinition of Myocardial Infarction European Society of Cardiology /American College of Cardiology /American Heart Association Consensus group and along with colleagues defined the 5 types of heart attacks.
He has given numerous International lectures including the Paul Dudley White lecture in 1994 at the American Heart Association. He has published over 1000 manuscripts and 3 books. He was recognised in the top 1% of scientists Worldwide Thompson and Reuters in 2014.
He has collaborated with many colleagues internationally in over 100 different trials. He has served on clinical events committees and data safety monitoring boards.
His special clinical interest is the management of patients with acute heart attacks and he is passionate about improving patient care.